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Objective. To compare the clinical characteristics of four human papillomavirus (HPV) assays: hybrid capture
2 (HC2), cobas, CLART, and APTIMA in Danish women with abnormal cytology.
Methods. SurePath samples from 367 consecutive women from Copenhagen, with atypical squamous cells of
undetermined signiﬁcance or worse, were tested with the four assays. These women were routinely recom-
mended for repeated testing or were referred for colposcopy. Their worst histological diagnosis in 29 months
from baseline was retrieved from the Danish National Pathology Data Bank.
Results.Of the 367women, 16 (4%) had no follow-up, 232 (63%) had bCIN2, 35 (10%) had CIN2, 81 (22%) had
CIN3, and 3 (1%) had cervical cancer. The sensitivity for ≥CIN3 was 95% (95% CI: 88–99) for HC2, 94% (95% CI:
87–98) for cobas, 93% (95% CI: 85–97) for CLART, and 87% (95% CI: 78–93) for APTIMA. In women of age
above 30 years, the sensitivities were 98% (95% CI: 87–100), 93% (95% CI: 80–98), 90% (95% CI: 77–97), and
93% (95% CI: 80–98), respectively. One woman with cervical cancer tested negative on CLART and one on
cobas; HC2 and APTIMA were positive in all three cancer cases. The speciﬁcity for bCIN3 was low for all assays
and varied between 22% and 35%. Similar results were seen for ≥CIN2.
Conclusions. Small differences in clinical characteristics were found for the four HPV assays in Danish women
with abnormal cytology aged ≥30 years. At younger ages, APTIMA was somewhat less sensitive for high-grade
CIN than the three HPV DNA assays.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cytology-based cervical screening has reduced the incidence of
cervical cancer. Nevertheless, it is in the future going to be replaced by
primary screeningwithmolecular humanpapillomavirus (HPV) testing,
which is more sensitive for detecting high-grade cervical intraepithelial
neoplasia (CIN) [1].
A change from cytology to molecular HPV testing is, however, still
challenging. Part of that challenge is to determine which assay would
offer the most favorable balance between detection of CIN and false-
positive test results generated by high assay sensitivity for detectionlth, University of Copenhagen,
).
. This is an open access article underof often inconsequential HPV infections. Studies that demonstrated
the beneﬁts of HPV testing over cytology in cervical screening utilized
a small number of different assays, predominantly the commercially
available hybrid capture 2 HPV Test (HC2; Qiagen, Gaithersburg, MD)
and in-house polymerase chain reaction (PCR) GP5+/6+ [2]. Since
then, more HPV assays have become commercially available, and
these need evaluation and documentation to inform decision making
based on assay performance, disease detection, and the burden of
follow-up testing and treatment.
An aim of the Danish Horizon study was to compare CIN detection
amongwomenwith abnormal cytologyusing four commercially available
HPV assays: HC2, cobas HPV Test (Roche Diagnostics, Pleasanton, CA),
CLART HPV2 Assay (Genomica, Madrid, Spain), and APTIMA HPV Test
(Hologic/Gen-Probe, San Diego, CA). The study had a split-sample design
nested into routine screening, utilizing fresh samples stored in SurePath.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Study design
Danish women are recommended for three-yearly cervical cancer
screening at age 23–49 and for ﬁve-yearly screening at age 50–
65 years. Those with atypical squamous cells of undetermined signiﬁ-
cance (ASCUS) aged ≥30 years have routine reﬂex HPV triage using
HC2. After a positive HC2 test result, they are referred for colposcopy,
as are women with high-grade squamous intraepithelial lesions
(HSIL), adenocarcinoma in situ (AIS), atypical squamous cells — cannot
exclude HSIL (ASC-H), atypical glandular cells (AGC), or squamous
carcinoma on cytology. Women with ASCUS age below 30 years, and
women with LSIL are recommended for repeated cytology testing in
six months, and are referred for colposcopy if any abnormalities are
detected at that point. While the study was ongoing, women with a
negative HC2 test result were recommended for repeated testing in
12 months.
The design of the Horizon study was described previously [3–6].
Brieﬂy, the study was nested into routine laboratory practice of the De-
partment of Pathology at Copenhagen University Hospital, Hvidovre.
Routine cytological evaluation on samples received between 10 June
and 25 August 2011 was undertaken by FocalPoint Slide Proﬁler and
GS Imaging System (BD, Burlington, NC). All cytology was evaluated
blinded to HPV test results, and reported using the Bethesda 2001 clas-
siﬁcation. The cytology post-quot material was used for HC2 testing.
Approximately 2 ml of residual SurePath material from each sample
were available for the study. This residual material was diluted with
2 ml of SurePath to obtain enough volume for testing on the remaining
three assays according to speciﬁc manufacturer agreed protocols. Spec-
imenswere aliquoted for cobas, CLART, andAPTIMA in no speciﬁc order.
Women were included in the present study if they had ≥ASCUS. At
baseline, the samples were categorized as primary screening or follow-
up samples based on the woman's history registered in the Danish
National Pathology Databank (Patobank) [7]. Theworst histology regis-
tered in the Patobank between the baseline date and 13 December 2013
was used in the analysis. Histological samples registered around the
same time as the baseline cytology sample (deﬁned as up to ﬁve days
before) were included. To conﬁrm the diagnoses of cervical cancer, an
expert pathologist from the same laboratory reviewed the free text of
the registered abnormal histologic material, blinded to the results of
HPV testing. All histology was routine, following colposcopy and biopsy
protocols as practiced by hospital and private gynecologists. In
Denmark, biopsies are to be taken from all suspicious areas after appli-
cation of acetic acid, and in case no lesions are visible random biopsies
are to be taken from all four quadrants.
Processing of samples and assay instrumentation
We compared the four HPV assays on all samples, and these were
handled and tested in the same laboratory by the same staff who are
involved in the laboratory's routine practice. They were trained and
certiﬁed by the assays' manufacturers. Testing protocols were agreed
upon prior to the study, and instrumentation and software were used
as supplied and maintained by the manufacturers for the duration of
the study.
Hybrid capture 2 HPV DNA testing
On the post-quot material from the cytology procedure, DNA was
either denatured prior to testing by pre-treating manually according
to themanufacturer's CE-IVD protocol, or DNAwas isolated and puriﬁed
using the DSP AXpH DNA kit on QIASymphony SP (Qiagen, Hilden,
Germany). As part of the cytology processing, post-quot material was
diluted approximately 1:1 in SurePath. Testing was undertaken on an
automated Rapid Capture System (Qiagen, Gaithersburg,MD). Followingthe standard procedures in the laboratory, aminority of samples used for
routine HC2 triage of women aged ≥30 years with ASCUS were dena-
tured and testedmanually. In these cases, HC2 testingwas not undertak-
en anew for the purposes of our study.
Cobas HPV DNA testing
1ml of the dilutedmaterialwas aliquoted into a 13ml round bottom
test tube (Sarstedt, cat. no. NC9018280), stored at 2 to 8 °C until testing.
No pre-treatment of SurePath samples was required. Extraction of DNA
was undertaken on cobas x480, and ampliﬁcation and detection of high
risk HPV DNA on cobas z480 analyzer in concordance with the
manufacturer's speciﬁcations.
CLART HPV DNA testing
1 ml of the diluted SurePath sample was spun down, with superna-
tant removed and cell pellet re-suspended in a mix of 180 μl phosphate
buffered saline (10× conc. pH 7.4, Pharmacy product) and 20 μl
proteinase K (recombinant, PCR Grade, Roche Diagnostics, Rotkreuz,
Switzerland). Samples were then vortexed and incubated for 1 h at
56 °C and 1 h at 90 °C. HPV DNA was puriﬁed using MagNa Pure LC 96
and MagNa Pure LC 32 instruments (Roche Diagnostics) with MagNa
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics). Polymerase
chain reaction ampliﬁcation was performed using CLART HPV2
Ampliﬁcation kit (Genomica). 5 μl of puriﬁed DNA were used for the
polymerase chain reaction ampliﬁcation, and low-density microarray
visualization was performed in concordance with the manufacturer's
speciﬁcations.
APTIMA HPV mRNA testing
1 ml of the diluted sample was aliquoted into an APTIMA Specimen
Transfer Tube containing 2.9 ml of buffered solution (Hologic/Gen-
Probe). The samples were treated with proteinase K prior to testing.
100 μl of the reconstituted proteinase K was added to each specimen
transfer tube and incubated at 65 °C for 2 h. The treated specimen
tube was stored at 2 to 8 °C until testing. Testing was performed on
the PANTHER platform.
Ethical considerations
Horizon was designed as a quality development study, utilizing only
residual material that would otherwise have been discarded. In
Denmark, informed consent from participating individuals is not re-
quired for quality development studies. Notiﬁcation to the Danish
Data Inspection Agency serves as ethical approval of register-based re-
search projects in which no contact is made to patients, their relatives
or treating physicians. The project has notiﬁcation number 2010-41-
5594.
Statistical analysis
A positive HPV testwas deﬁned according to themanufacturers' rec-
ommendations (HC2: relative light unit per cut off value ≥1; cobas
channels 16, 18, and 12 other high risk genotypes: critical threshold
values ≤40.5, ≤40.0, and ≤40.0, respectively; APTIMA: signal to cut
off value ≥0.5). CLART was considered positive if at least one of the 13
HPV genotypes classiﬁed as high risk by the International Agency for
Research on Cancer, including genotype 68, was detected [8].
The proportion of ≥CIN2 and≥CIN3 with a positive HPV test result
(i.e., the proportion of high-grade CIN that was detected by a particular
assay) was used as an indicator of an assay's clinical sensitivity. As an
indicator of an assay's clinical speciﬁcity, we calculated the proportion
of women testing negative on the assay among those with bCIN3
and bCIN2, respectively. We assumed that women with cytology but
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without any additional cervical test as lost to follow-up from this calcu-
lation. The 95% conﬁdence intervals (CI) for sensitivity and speciﬁcity
were calculated using binomial distribution. We calculated the relative
sensitivity and speciﬁcity for cobas, CLART, and APTIMA by comparing
their sensitivity and speciﬁcity to that of HC2 [9]. The 95% CI for relative
sensitivity and relative speciﬁcity were calculated assuming that their
logarithms were approximately normally distributed.
Positive agreement was calculated as the conditional probability
that all compared assays were positive given that at least one was
positive [6]. Cohen's unweighted κ-coefﬁcients of overall agreement
were calculated using the standard formula for each combination of
two assays, and their 95% CI were calculated by analyzing 1000
bootstrap replications (IBM SPSS Statistics Ver19). κ values above 0.60
were considered to indicate “substantial” agreement [10].
The Horizon study size was set to 5000 samples based on capacity
and processing considerations, and ﬁnally 5064 consecutive routine
samples from 5034 women were included. The 30 excluded samples
were the second or third samples from the same woman; in women
withmultiple samples,we retained thosewith themost severely abnor-
mal cytology (as this would deﬁne how thewomanwas to bemanaged
following the routine screening recommendations), or, in case of the
same cytological diagnosis, having a higher number of positive HPV
test results within the Horizon study. Among the 5034 women with
one sample each, 367 (7.3%) had abnormal cytology (Table 1), and all
were included in this study.
Results
Among the 367 women, 122 (33%) had ASCUS, 18 (5%) ASC-H or
AGC, 142 (39%) LSIL, and 85 (23%) ≥HSIL on cytology at baseline.
Most, 331 (90%), women were 23–65 years, i.e. in the target age
group for the Danish cervical cancer screening program. About two-
thirds, 241 (66%), had their sample taken in primary screening. In
total, 270 (74%) had a biopsy taken, and a further 69 (19%) had normalTable 1
The Horizon study: Description of 367 women with abnormal cytology.
Characteristics N (column %) Worst outcome during follow-up (row %)





Total 367 (100%) 16 (4%) 69 (19%) 12 (3%)
Cytology
ASCUS 122 (33%) 5 (4%) 31 (25%) 8 (7%)
ASC-H, AGC 18 (5%) 0 (0%) 0 (0%) 0 (0%)
LSIL 142 (39%) 9 (6%) 38 (27%) 4 (3%)
≥HSIL 85 (23%) 2 (2%) 0 (0%) 0 (0%)
Age (years)
b23 33 (9%) 0 (0%) 5 (15%) 0 (0%)
23–29 145 (40%) 6 (4%) 25 (17%) 4 (3%)
30–39 104 (28%) 2 (2%) 22 (21%) 3 (3%)
40–49 48 (13%) 5 (10%) 10 (21%) 0 (0%)
50–59 21 (6%) 2 (10%) 4 (19%) 3 (14%)
60–65 13 (4%) 1 (8%) 3 (23%) 1 (8%)
N65 3 (1%) 0 (0%) 0 (0%) 1 (33%)
Screening history
Screeninga 241 (66%) 16 (7%) 58 (24%) 8 (3%)
Follow-upa 126 (34%) 0 (0%) 11 (9%) 4 (3%)
Results of HPV testing
HC2 + 300 (82%) 12 (4%) 40 (13%) 6 (2%)
Cobas + 282 (77%) 9 (3%) 41 (15%) 8 (3%)
CLART + 269 (73%) 9 (3%) 36 (13%) 7 (3%)
APTIMA + 256 (70%) 10 (4%) 31 (12%) 5 (2%)
a Follow-up samples: deﬁned as sampleswith an earlier diagnosis of cervical cancer, a diagno
withmore severe cytological abnormalities or a positive HPV test in the past 12 months. Other s
screening samples and a small proportion of samples taken by indication.follow-up cytology and/or HPV test results, indicating that high-grade
CIN lesions were unlikely.
During on average 29 months since baseline, 16 (4%)womenhad no
follow-up. A further 81 (22%) had new cytology but no histology;
cytology was normal in 69 of these women. The remaining 270 (74%)
women had histological follow-up, including 119 (32%) women with
CIN2, CIN3, or cervical cancer. Completeness of follow-up among
women with positive HPV test results varied little by assay.
No invalid test result owing to technical failures or insufﬁcient geno-
mic material was observed. In total, 300 (82%) women tested positive
on HC2, 282 (77%) on cobas, 269 (73%) on CLART, and 256 (70%) on
APTIMA. Positive agreement between the assays was relatively good,
as 233 (74%) of 317 women testing positive on at least one HPV assay
tested positive on all four (Table 2). As expected, agreement increased
with cytological abnormality, and itwas alsohigher inwomenwith sub-
sequent ≥CIN2 compared to women with ≤CIN1. Overall agreement
between all assays measured by the κ-coefﬁcient was substantial
(Table 3).
HC2 detected 80 out of 84≥CIN3 (Table 1; sensitivity: 0.95, 95% CI:
0.88–0.99, Table 4). Cobas detected 79 (sensitivity: 0.94, 95% CI: 0.87–
0.98), CLART 78 (sensitivity: 0.93, 95% CI: 0.85–0.97), and APTIMA 73
≥CIN3 (sensitivity: 0.87, 95% CI: 0.78–0.93). Overall, APTIMA detected
signiﬁcantly fewer ≥CIN3 than HC2 (relative sensitivity: 0.91 (95% CI:
0.83–1.00)), whereas the differences between HC2 and cobas or
CLART were not signiﬁcant. However, the lower detection by APTIMA
was conﬁned to women aged b30 years (Fig. 1), relative sensitivity vs.
HC2: 0.88 (95% CI: 0.74–1.03). In women aged ≥30 years, APTIMA
detected a similar number of ≥CIN3 as HC2 (relative sensitivity 0.95
(95% CI: 0.86–1.05)), and also a similar number as cobas and CLART.
The patterns were similar with endpoint of ≥CIN2.
Overall, only a minority of women with bCIN3 tested negative on
the four HPV assays. The speciﬁcity for bCIN3 was similar for cobas
and HC2 (relative speciﬁcity 1.24 (95% CI: 0.92–1.67)), but was signiﬁ-
cantly higher for CLART (relative speciﬁcity 1.44 (95% CI: 1.08–1.92)),







CIN1 CIN2 CIN3 Cervical cancer
11 (3%) 82 (22%) 58 (16%) 35 (10%) 81 (22%) 3 (1%)
4 (3%) 30 (25%) 18 (15%) 9 (7%) 17 (14%) 0 (0%)
1 (6%) 2 (11%) 2 (11%) 4 (22%) 9 (50%) 0 (0%)
6 (4%) 36 (25%) 29 (20%) 12 (8%) 8 (6%) 0 (0%)
0 (0%) 14 (16%) 9 (11%) 10 (12%) 47 (55%) 3 (4%)
3 (9%) 8 (24%) 6 (18%) 5 (15%) 6 (18%) 0 (0%)
4 (3%) 30 (21%) 22 (15%) 17 (12%) 37 (26%) 0 (0%)
2 (2%) 24 (23%) 15 (14%) 6 (6%) 28 (27%) 2 (2%)
0 (0%) 11 (23%) 12 (25%) 4 (8%) 6 (13%) 0 (0%)
2 (10%) 5 (24%) 1 (5%) 2 (10%) 2 (10%) 0 (0%)
0 (0%) 3 (23%) 2 (15%) 1 (8%) 1 (8%) 1 (8%)
0 (0%) 1 (33%) 0 (0%) 0 (0%) 1 (33%) 0 (0%)
7 (3%) 44 (18%) 28 (12%) 19 (8%) 60 (25%) 1 (b1%)
4 (3%) 38 (30%) 30 (24%) 16 (13%) 21 (17%) 2 (2%)
9 (3%) 65 (22%) 54 (18%) 34 (11%) 77 (25%) 3 (1%)
8 (3%) 55 (20%) 48 (17%) 34 (11%) 77 (27%) 2 (1%)
9 (3%) 51 (19%) 45 (16%) 34 (12%) 76 (28%) 2 (1%)
8 (3%) 49 (19%) 47 (18%) 33 (12%) 70 (27%) 3 (1%)
sis of cervical intraepithelial neoplasia in≤3 years, with ASCUS in the previous 15 months,
amples were considered to be primary samples; reﬂecting routine practice, these included
Table 2
Positive agreement of HPV assays by concurrent cytology, and by subsequent histology. Proportions based on women with at least one positive HPV test.




















4 positive 233 (74%) 53 (62%) 13 (87%) 96 (72%) 71 (86%) 44 (64%) 40 (71%) 31 (89%) 68 (85%) 1 (33%)
3 positive 38 (12%) 16 (19%) 1 (7%) 14 (11%) 7 (8%) 9 (13%) 8 (14%) 3 (9%) 6 (8%) 2 (67%)
2 positive 15 (5%) 9 (10%) 1 (7%) 4 (3%) 1 (1%) 1 (1%) 2 (4%) 1 (3%) 4 (5%) 0 (0%)
1 positive 31 (10%) 8 (9%) 0 (0%) 19 (14%) 4 (5%) 15 (22%) 6 (11%) 0 (0%) 2 (3%) 0 (0%)
≥1 positivea 317 (86%) 86 (70%) 15 (83%) 133 (94%) 83 (98%) 69 (84%) 56 (97%) 35 (100%) 80 (99%) 3 (100%)
DNA assays
3 positive 254 (81%) 66 (77%) 14 (93%) 99 (75%) 75 (91%) 50 (74%) 43 (78%) 33 (94%) 73 (91%) 1 (33%)
2 positive 28 (9%) 10 (12%) 1 (7%) 14 (11%) 3 (4%) 3 (4%) 6 (11%) 1 (3%) 4 (5%) 2 (67%)
1 positive 33 (10%) 10 (12%) 0 (0%) 19 (14%) 4 (5%) 15 (22%) 6 (11%) 1 (3%) 3 (4%) 0 (0%)
≥1 positivea 315 (86%) 86 (70%) 15 (83%) 132 (93%) 82 (96%) 68 (83%) 55 (95%) 35 (100%) 80 (99%) 3 (100%)
a Proportions calculated using all women in the cytological or histological category as the denominator. Proportions in other rows had the total number of samples positive on≥1 HPV
assay as the denominator.
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≥30 years than among younger women. The patterns were similar
with endpoint of bCIN2.
Among these 367 women, three had cervical cancer with a cytolog-
ical diagnosis of HSIL (Table 5). One woman tested positive on all four
HPV assays. Another woman tested positive on HC2, cobas and
APTIMA, but her CLART test result showed only an infection with a
low-risk HPV genotype (HPV 70). In this woman, cobas detected HPV
18, but the signal was weak, which was also the case on APTIMA. The
third woman tested positive on HC2, CLART, and APTIMA. Her cobas
test result was negative on all three channels, whereas the assay's inter-
nal control showed the sample's genomic material to be sufﬁcient. In
this woman, CLART detected an infection with HPV 16.
Discussion
Most Danishwomenwith abnormal cytology tested positive for HPV
on all four evaluated assays, HC2, cobas, CLART, and APTIMA. Hence, the
differences between the assays in terms of detection of≥CIN2 or≥CIN3
were small and insigniﬁcant. In women younger than 30 years, where
HPV testing is not currently routinely recommended in Denmark,
APTIMA detected fewer CIN than the three DNA assays. However, in
women aged ≥30 years APTIMA detected a similar number of ≥CIN2
and ≥CIN3. For all assays, furthermore, the speciﬁcity improved with
age.
The Horizon studywas a population-based split-sample study utiliz-
ing material from consecutive routine samples. Histological outcomes
were therefore representative for the assays' performance in a routine
screening setting. Follow-up was done passively by linkage to the
Patobank, which has been virtually complete at the national level
since the late 2000s. Hence, all women who kept their residence in
Denmark during the follow-up period could be accounted for in these
data. Only 4% of the women were completely lost to follow-up.
Unlike the majority of previous studies comparing HPV assays, all
samples in the Horizon study were collected and stored in SurePath.
Though SurePath is the second most widely used liquid-based cytologyTable 3
Kappa-coefﬁcients of overall agreement for the four HPV assays.










HC2 Cobas 54 269 31 13 0.64 (0.52–0.73)
HC2 CLART 57 259 41 10 0.61 (0.51–0.70)
HC2 APTIMA 63 252 48 4 0.62 (0.53–0.71)
Cobas CLART 78 262 20 7 0.80 (0.73–0.87)
Cobas APTIMA 75 246 36 10 0.68 (0.59–0.76)
CLART APTIMA 81 239 30 17 0.69 (0.59–0.77)mediumworldwide after ThinPrep, only limited evidence on the clinical
and technical performance of HPV assays is available for it. Furthermore,
all samples were tested while they were fresh, which sets the Horizon
study apart from studies that relied on archived material [11–17].
Fresh samples are representative for use of HPV testing in routine
screening. When archived, particularly in longer-term, samples may
start losing their original biological content as a consequence of random
biological degradation. Hence, low-level infections that would have
been detected in fresh samples may be missed in archived samples.
Our study was limited by the number of consecutive samples to be
tested (n = ca. 5000, including women with normal cytology), which
was agreed with themanufacturers prior to the study, and took into ac-
count the laboratory's practical considerations. The 367 (7.3%) women
with abnormal cytology reﬂected the routine proportion of cytology-
abnormal samples in an unselected population from the laboratory's
catchment area. The sensitivity of HPV assays for high-grade CIN is gen-
erally high, and the differences between the assays tend to be small.
Hence, despite a high prevalence of high-grade CIN in women with cy-
tological abnormalities itwould be necessary to include very large num-
bers of women to have a fully powered study. In our study, the highest
detection rate of≥CIN2 for anHPV assaywas 114/367 (31 per 100), and
the lowest 106/367 (29 per 100). An ex-post power calculation for this
difference in the detection rates revealed that N8200womenwith cyto-
logical abnormalities would need to be included in the study, which is
substantially more than any previous study has reported.
Another limitation of our study was that womenwith ASCUS or LSIL
who only had cytology in their follow-up (n= 81) were assumed to be
CIN-free. However, almost all of thesewomen (n=69, 85%) had normal
follow-up cytology, and, considering the low risk in this case, routine
histological veriﬁcation was not justiﬁable. Nevertheless, it is well
established that repeated cytology may still miss high-grade CIN. In a
meta-analysis, the relative detection of ≥CIN2 in follow-up of ASCUS
was 1.27 for HPV testing compared to repeated cytology, and for LSIL
it was 1.23 [18]. If the same was true in our data, we estimated that
eight ≥CIN2 may have been left undetected. The eight cases would
have only marginally increased the total ≥CIN2 detection rate in our
study, from 32.4 per 100 (119/367) to 34.6 per 100 (127/367).
In our study, cobas and CLART each missed one case of cervical can-
cer. Both are L1 primer-based PCR assays. However, by rule of mutual
exclusion — both cases of cervical cancer were detected by one and
missed by the other L1 assay—we conclude that L1 deletions probably
did not play a role. Furthermore, HPV-negative cervical cancers have
been previously reported also for HC2 and APTIMA. In a German study
using archived samples from women referred for colposcopy, one out
of 13 cancers wasmissed by APTIMA, and two by HC2 [13]. In a Canadi-
an colposcopy referral study, one of 13 cancers was negative on HC2
[19]. The impact of missed prevalent cervical cancers is widely debated
Table 4
Sensitivity and speciﬁcity of HPV assays, and relative sensitivity and speciﬁcity compared to hybrid capture 2, for detection of ≥CIN3 and ≥CIN2, all ages.
Hybrid capture 2 Cobas CLART APTIMA
Endpoint: ≥CIN3
Sensitivity (95% CI) 0.95 (0.88–0.99) 0.94 (0.87–0.98) 0.93 (0.85–0.97) 0.87 (0.78–0.93)
Relative sensitivity (95% CI) 1.00 (Ref) 0.99 (0.92–1.06) 0.98 (0.90–1.05) 0.91 (0.83–1.00)
Speciﬁcity (95% CI) 0.22 (0.17–0.28) 0.27 (0.22–0.33) 0.32 (0.26–0.38) 0.35 (0.29–0.41)
Relative speciﬁcity (95% CI) 1.00 (Ref) 1.24 (0.92–1.67) 1.44 (1.08–1.92) 1.59 (1.21–2.10)
Endpoint: ≥CIN2
Sensitivity (95% CI) 0.96 (0.90–0.99) 0.95 (0.89–0.98) 0.94 (0.80–0.98) 0.89 (0.82–0.94)
Relative sensitivity (95% CI) 1.00 (Ref) 0.99 (0.94–1.05) 0.98 (0.93–1.04) 0.93 (0.86–1.00)
Speciﬁcity (95% CI) 0.25 (0.20–0.31) 0.31 (0.25–0.37) 0.36 (0.30–0.43) 0.40 (0.33–0.46)
Relative speciﬁcity (95% CI) 1.00 (Ref) 1.24 (0.93–1.67) 1.45 (1.09–1.92) 1.59 (1.21–2.09)
Women lost to follow-up (n = 16, Table 1) were excluded.
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It should though be noted that, to some extent, false-negative screening
tests are unavoidable in any cancer screening program despite
advanced technology. Laboratory quality assurance/quality control
programs will play a crucial role in preventing these screening errors.
Furthermore, despite the occasional ﬁnding of HPV-negative cervical
cancers, the observed overall frequencies of false-negative test results
are, for virtually all major HPV assays, signiﬁcantly lower than they
have been for cytology [1,20,21].
Other studies comparing cobas, CLART or APTIMA with HC2 in
women with cervical abnormalities using ThinPrep samples largely
agreedwith ours [11,13,16,17,19,22–35]. Comparing cobas to HC2, sim-
ilar sensitivity and speciﬁcity for ≥CIN2 and ≥CIN3 were observed
amongwomenwith ASCUS [17,27], whereas in women referred for col-
poscopy a slightly higher speciﬁcity was observed for cobas [24,35]. For
CLART compared to HC2, two Portuguese studies using archived sam-
ples from women attending primary and gynecological outpatient
clinics found a similar sensitivity and speciﬁcity for ≥CIN2 [11,22], al-
though, citing “technical problems during the evaluation”, the sensitiv-
ity of CLART for≥CIN2 and≥CIN3was lower and the speciﬁcity higher
in a UK colposcopy referral population [23]. The UK and one of the Por-
tuguese studies did not ﬁnd substantial differences in the speciﬁcity of
CLART between women aged b30 years and those aged ≥30 years
[22,23]. Finally, in several studies APTIMA had a similar sensitivity for
≥CIN2 and/or ≥CIN3 as HC2 and a signiﬁcantly better speciﬁcity [13,
19,23,24,28,36]. In the UK colposcopy referral population, APTIMA's
sensitivity for ≥CIN2 was slightly lower in women aged b30 yearsFig. 1. Sensitivity and speciﬁcity (endpoint:≥CIN3) for hybrid capture 2, cobas, CLART and APT
CI: 0.84–0.99), CLART 0.95 (95% CI: 0.84–0.99), APTIMA 0.81 (95% CI: 0.67–0.92). Speciﬁcity: HC
APTIMA 0.19 (95% CI: 0.12–0.26).≥30 years. Sensitivity: HC2 0.98 (95% CI: 0.87–1.00), cobas 0
Speciﬁcity: HC2 0.37 (95% CI: 0.29–0.46), cobas 0.44 (95% CI: 0.36–0.53), CLART 0.47 (95% CI:than in older women [23]. Finally, using long-term stored samples in
the German study [13], no major age-related differences in APTIMA's
sensitivity were reported.
Comparing HPV assays in women with abnormal cytology (referral
population studies) is a commonly used assay evaluation shortcut.
One of the advantages of such studies is that the women are already
routinely recommended for follow-up, limiting the need to build com-
plex and costly trial infrastructures. Another advantage is that in these
women the prevalence of high-grade CIN is relatively high, meaning
that a smaller number of women need to be enrolled to obtain satisfac-
tory statistical power for detection of CIN. By deﬁnition, however, all CIN
in studies of women with cytological abnormalities are detectable by
cytology (i.e., the sensitivity of cytology for these CIN is 100%), and if it
was for these CIN alone, HPV testing would not need to be introduced.
Rather, HPV testing is an attractive option to detect CINmissed by cytol-
ogy in primary screening. The challenge in primary screening, however,
is the uncertainty on the relative performance of HPV assays. In contrast
to the herein reported data on womenwith abnormalities, a substantial
rate of disagreement between the four assays in detecting HPV infec-
tions was documented for screening samples from our study [6]. This
ﬁnding was supported by the scarce data from previous studies [6].
One may speculate that screening samples include HPV infections
with a much wider distribution of viral loads compared to samples
with cervical abnormalities. Hence, while referral population studies
may give valid data on the characteristics of HPV assays for e.g. triage
settings, their conclusions should be only cautiously applied to primary
screening settings.IMA, by age. Legend: b30 years. Sensitivity: HC2 0.93 (95% CI: 0.81–0.99), cobas 0.95 (95%
2 0.06 (95% CI: 0.03–0.12), cobas 0.09 (95% CI: 0.05–0.16), CLART 0.16 (95% CI: 0.10–0.23),
.93 (95% CI: 0.80–0.98), CLART 0.90 (95% CI: 0.77–0.97), APTIMA 0.93 (95% CI: 0.80–0.98).
0.39–0.56), APTIMA 0.51 (95% CI: 0.42–0.59).
Table 5
Description of baseline HPV results in three women with cervical cancer.
Case Screening history Cytology HC2 result (rlu/co value) Cobas result (CT valuea) CLART result (detected genotypes) APTIMA result (s/co value)
1 Follow-up sample HSIL Positive (11.88) Positive (HPV 16: 28.6) Positive (HPV 16) Positive (13.90)
2 Follow-up sample HSIL Positive (21.43) Positive (HPV 18: 39.5) Negative (HPV 70) Positive (0.84)
3 Primary sample HSIL Positive (92.02) Negativeb Positive (HPV 16) Positive (11.10)
a In positive channels.
b CT-β value: 28.9.
479M. Rebolj et al. / Gynecologic Oncology 135 (2014) 474–480In conclusion, small differences in clinical characteristicswere found
for HC2, cobas, CLART, and APTIMA in women from Copenhagen with
abnormal cytology at age ≥30 years. At younger ages where HPV test-
ing is currently not routinely recommended in Denmark, however,
APTIMA showed a somewhat lower sensitivity for detecting high-
grade CIN than the three HPV DNA assays.
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